|
Senior Management
Steven T. Downey
President and Chief Executive Officer
Mr. Downey is ApoImmune's President and CEO and also serves as Chairman of Board of Directors. Mr. Downey has over 28 years of business experience including 23 years in senior leadership positions with both start-ups and large public corporations. He previously served as the acting CEO and COO of MetaCyte Business Lab LLC, the life sciences business accelerator in Louisville, KY. In 2004, Mr. Downey was named by former Kentucky Governor Ernie Fletcher to the Kentucky Life Sciences Advisory Consortium and was a member of the Board of Directors of the Kentucky Life Sciences Organization. Previously, as Executive Vice President and CFO of Ventas, Inc., a NYSE $200 million revenue real estate investment trust, Mr. Downey actively participated in the restructuring of Vencor, Inc., its primary tenant. At Providian Corporation, he was responsible for the financial operations of the holding company and three divisions with over $20 billion in assets and $2 billion in revenue. He also spent over 12 years with Ernst & Young serving primarily publicly-held clients in the financial services, real estate and health care fields.
Haval Shirwan, Ph.D.
Chief Scientific Officer and Founder
Dr. Shirwan is the Founder and CSO of ApoImmune and also a member of the Board of Directors. He is Professor in the Department of Microbiology and Immunology at the University of Louisville, and is the Director of the Molecular Immunomodulation Program at the Institute for Cellular Therapeutics at Louisville. He is also the Hamilton Chair in Autoimmune Disease and a University Scholar at the School of Medicine.
Throughout his career Dr. Shirwan has maintained a focus on clinically relevant details of the immune response. Dr. Shirwan investigated the molecular basis of the effects interferons on the replication of viruses during his graduate studies at the University of California, Santa Barbara. His postdoctoral work at the California Institute of Technology dealt with the structure and function of major histocompatibility complex antigens. He was recruited from Caltech to start the Molecular Immunology Program at Cedars/Sinai Medical Center in Los Angeles with a focus on transplantation immunology. After a brief tenure at the Alleghany University of Health Sciences in Philadelphia, PA, Dr Shirwan joined the faculty of the University of Louisville in 1998. In recent years, Dr. Shirwan has focused on translational research and pioneered the ProtEx technology, the Company's platform technology, as a safe, efficient, and practical alternative to DNA-based immune gene therapy for immunomodulation.
Dr. Shirwan has served on numerous study sections for national and international funding agencies, including the National Institutes of Health, the Veteran's Administration, The U.S.-Israel Binational Science Foundation, Israel Science Foundation, American Heart Association, Wellcome Trust, and Philip Morris USA Inc. He has also served on the Editorial Board of the journal Graft, was Section Editor for Current Opinion in Organ Transplantation, and an ad hoc reviewer for numerous scientific journals. He is the member of several scientific organizations and authored more than 100 papers, reviews, and book chapters. He has lectured at various national and international scientific meetings as an invited speaker. Dr. Shirwan's numerous honors and recognitions include the following organizations and awards: the North Atlantic Treaty Organization, the Red Cross, an NIH First Independent Research Support & Transition (FIRST) award, the American Society of Transplant Physicians-Ortho Award, the Cedars-Sinai Medical Center Young Investigator Award, and the Louisville Business First, Partners in Health Care Award.
For additional information, please visit Dr. Shirwan's University of Louisville web site.
Rolf M. Huseby, Ph.D.
Vice President, Manufacturing and Quality Assurance
Dr. Huseby has over 30 years of experience in the pharmaceutical, biotechnology, medical diagnostics and devices, and chemical business areas and has held senior management positions in four Fortune 500 companies. Dr. Huseby served as Vice President of Clinical Systems Development and Vice President of Applied Research and Advanced Development for SmithKline Beckman. At Baker Diagnostics, Dr. Huseby was Vice President of Research and Development and of the Strategic Business Center of Hematology and Immunology. At DADE Division of Baxter Laboratories, Dr. Huseby served as Director of Research and Development. Prior to that, he conducted pharmaceutical research for Eli Lilly and Company. Dr. Huseby was appointed the first industry representative to the FDA Classification panels for in vitro diagnostics. He is experienced in all phases of product research and development and business management. Dr. Huseby received his B.S. degree in Chemistry and Mathematics, and his Ph.D. in Chemistry from the University of Louisville. For his postdoctoral work, Dr. Huseby served as a senior fellow in Molecular Pathology at the University of Louisville School of Medicine.
Kathryn MacLeod, Ph.D.
Director, Research and Development
Dr. MacLeod joined the company in 2005, and has more than 12 years of industry experience including both start-up biotechnology and large pharmaceutical companies, including Genzyme Tissue Repair, Velcura Therapeutics, and Pfizer Global Research and Development. In addition to overseeing all aspects of the R&D activities and expansion of the technology portfolios, she also serves as the Company's Grants Administrator and Principle Investigator on numerous grants. In her role as Grants Administrator, Dr. MacLeod has been instrumental in procuring funding from both state and federal agencies, resulting in over $5 MM in the last two years. She also serves as an ad hoc reviewer for granting agencies such as the National Institutes of Health (NIH). Dr. MacLeod received her B.S. degree in Biology from Emmanuel College, Boston, and her graduate degree in Cellular and Molecular Physiology from Tufts University School of Medicine in Boston. She completed her postdoctoral work at Pfizer Global Research and Development, Ann Arbor, MI.
Dr. Joseph Meuth, Ph.D.
Director, Protein Purification Group
Dr. Meuth has recently joined ApoImmune and has over 25 years senior management experience at
Abbott Laboratories and Novartis Institute of Biomedical Sciences. He is an innovative protein biochemist
with expertise in protein isolation and characterization of recombinant proteins and potential biologics,
assay development, and the use of proteomics for target discovery/profiling. Dr. Meuth received his B.S.
degree in Biochemistry from Centre College, KY, and his Ph.D. in Biological Chemistry with a minor in
Analytical Chemistry from Indiana University, Bloomington, IN. Dr. Meuth then completed a postdoctoral
fellowship at the Scripps Clinic and Research Foundation, La Jolla, CA.
back to Leadership
|
|
|
